Details of the Drug Combination

General Information of Drug Combination (ID: DCYTXVB)

Drug Combination Name
Tivantinib TG100801
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs Tivantinib   DMNVP8Q TG100801   DMPH1AG
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 35.988
Bliss Independence Score: 35.941
Loewe Additivity Score: 5.73
LHighest Single Agent (HSA) Score: 9.276

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Tivantinib
Disease Entry ICD 11 Status REF
Hepatocellular carcinoma 2C12.02 Phase 3 [2]
Solid tumour/cancer 2A00-2F9Z Phase 3 [3]
Tivantinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of TG100801
Disease Entry ICD 11 Status REF
Macular degeneration 9B78.3 Phase 2 [4]
TG100801 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor (VEGF) TT9HKJA VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
4 ClinicalTrials.gov (NCT00509548) Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD. U.S. National Institutes of Health.
5 Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37.